Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Allergan : Trump to keep Obama rule curbing corporate tax inversion deals

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 04:55pm CET
U.S. President Donald Trump departs Washington aboard Air Force One

(This October 4 story fixes comment by Organization for International Investment as referring to historically foreign-based companies in paragraph 13.)

President Donald Trump ordered a review almost six months ago of tax rules from the final months of the Obama administration, including ones to discourage companies from redomiciling abroad for tax reasons.

"Treasury plans to retain the distribution requirements under Section 385 pending enactment of tax reform," the department said in a statement, adding "these regulations are necessary to safeguard against earnings stripping."

It also said it planned to revoke and streamline some related documentation rules.

A 2011-2015 wave of inversion deals prompted Treasury to take a series of actions that culminated in an April 2016 rule release and the collapse of a $160-billion deal between U.S. drugmaker Pfizer Inc (>> Pfizer) and Ireland’s Allergan Plc (>> Allergan plc), which would have been the largest inversion ever.

Tax inversions occur when a U.S. company is acquired by a smaller foreign business from a low-tax country and adopts its domicile to reduce the combined firm’s overall U.S. tax burden.

The Section 385 rule was part of Obama's anti-inversion effort and was finalized a year ago. It was meant to combat a corporate tax-reduction technique known as earnings stripping.

Earnings stripping occurs when the U.S. subsidiary of a newly inverted company loads up on debt and avoids taxes on its domestic profits by sending them overseas to the foreign parent in the form of tax-deductible interest payments.

The Obama rule reclassified some forms of debt as equity, changing tax-exempt interest payments into taxable dividends and making earnings stripping strategies more difficult to pursue.

The Organization for International Investment (OFII), a Washington lobbying group for foreign-based companies with U.S. operations, praised the documentation portion of Treasury's latest move and criticized the retention of the rest of the Section 385 rule.

"Unfortunately, in perpetuating an unsubstantiated premise of the Obama administration, Treasury has decided to keep part of these discriminatory regulations," the group said.

Companies with historic foreign headquarters that have expanded into the United States, OFII said in a statement, "are not overleveraged, their debt levels have remained largely flat and their interest expense has declined while their investments into America’s economy have grown."

The Treasury Department said it expected a Republican proposal to overhaul the tax code would eliminate the need for anti-inversion rules. The proposal would sharply cut the corporate tax rate and end taxation of multinationals' foreign profits.

(Writing by Kevin Drawbaugh; Editing by Susan Thomas)

Stocks treated in this article : Allergan plc, Pfizer
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
04:15p ALLERGAN : Receives FDA Clearance for the CoolSculpting Treatment to Improve App..
12/13 TEVA PHARMACEUTICAL INDUSTRIES : Fears of Israeli job cuts at Teva sparks call f..
12/12 ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/07 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
12/07 EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
11/30 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/29DJALLERGAN : Health Care Up on Rotation Out of Tech -- Health Care Roundup
More news
News from SeekingAlpha
04:07a YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
03:17a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
12/13 Top 10 Net Payout Yields For December 2017
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
Financials ($)
Sales 2017 15 894 M
EBIT 2017 7 658 M
Net income 2017 -6 486 M
Debt 2017 24 765 M
Yield 2017 1,69%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,10x
EV / Sales 2018 5,06x
Capitalization 56 286 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 225 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-20.10%56 286
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214